Growth Hormone Deficiency in Children: Peptides
Peptide Growth Therapies
8-10 cm/year
First-year growth velocity on recombinant growth hormone therapy in children with GH deficiency, representing catch-up growth.
KIGS Database, JCEM, 2022
KIGS Database, JCEM, 2022
View as imageGrowth hormone deficiency (GHD) in children is one of the few endocrine conditions where peptide-based therapy is the established standard of care rather than an investigational approach. Recombinant human growth hormone (rhGH), a 191-amino-acid peptide identical to pituitary-derived GH, has been used to treat pediatric GHD since the mid-1980s. More than 90% of children with isolated GHD who receive adequate treatment reach adult height within the normal range. The broader question of what evidence supports peptide therapy for short stature extends beyond GHD into conditions like Turner syndrome, idiopathic short stature, and small for gestational age.
Beyond recombinant GH itself, several peptide-based alternatives and adjuncts have been studied in children with growth failure. Growth hormone-releasing peptides (GHRPs), growth hormone-releasing hormone (GHRH) analogs, and GH secretagogues represent approaches that stimulate endogenous GH production rather than replacing it directly. This article examines the evidence behind each option.
Key Takeaways
- Recombinant human growth hormone (rhGH) produces first-year growth velocity of 8-10 cm/year in GH-deficient children, with over 90% reaching normal adult height range (KIGS database, 2022)
- Intranasal GHRP-2 increased growth velocity versus pretreatment and post-treatment periods in GH-deficient children, though serum IGF-1 levels did not rise significantly (Pihoker et al., 1997)
- Oral ibutamoren mesylate (MK-677) increased mean 24-hour GH concentration, peak GH, and IGF-1 levels in GH-deficient children in a controlled trial (Codner et al., 2001)
- CJC-1295, a long-acting GHRH analog, normalized GH and IGF-1 levels with once-daily dosing in healthy adults, maintaining pulsatile GH secretion (Teichman et al., 2006)
- Daily GH injections (6-7 per week) produce better growth responses than three-times-weekly dosing, but adherence declines over multi-year treatment
- Long-acting weekly GH formulations (somatrogon, lonapegsomatropin, somapacitan) show non-inferior height velocity compared to daily GH in recent phase III trials
Recombinant Human Growth Hormone: The Standard Treatment
Recombinant human growth hormone has been the foundation of pediatric GHD treatment since biosynthetic production replaced cadaveric pituitary-derived GH in 1985. The switch eliminated the risk of Creutzfeldt-Jakob disease transmission and made GH therapy widely available.
How rhGH Therapy Works
rhGH is administered by subcutaneous injection, typically once daily (6-7 injections per week). The recommended initial dose for pediatric GHD ranges from 0.16 to 0.24 mg/kg/week. Despite the fact that normal GH secretion occurs in multiple pulsatile bursts throughout the day and night, a single daily injection maintains adequate IGF-1 levels and produces effective growth stimulation.[1]
The best growth response occurs in the first year of treatment, with catch-up growth velocities of 8-10 cm/year in children with isolated GHD. Growth velocity gradually declines in subsequent years but remains above pretreatment rates. The KIGS database (Kabi International Growth Study), one of the largest post-marketing surveillance programs for rhGH, followed tens of thousands of children and confirmed that more than 90% of children diagnosed with GHD achieved normal final adult height.
Factors Affecting Response
Several variables influence how well a child responds to rhGH. Younger age at treatment initiation, greater height deficit at baseline, higher GH dose, and the severity of GH deficiency all predict better first-year growth velocity. Children with multiple pituitary hormone deficiencies tend to have more severe growth failure but also respond robustly to replacement therapy when all deficient hormones are addressed.
Adherence is a critical and often underappreciated factor. Daily injections for years impose a substantial burden on children and families. Studies consistently show that poor adherence, missing even 1-2 injections per week, produces measurably lower annual height velocity compared to children with good compliance. This adherence challenge has driven interest in both longer-acting GH formulations and alternative peptide approaches that might reduce injection frequency.
Growth Hormone-Releasing Peptides in Children
Growth hormone-releasing peptides (GHRPs) are synthetic peptides that stimulate GH release from the pituitary through the growth hormone secretagogue receptor (GHS-R1a), later identified as the ghrelin receptor. Unlike rhGH, which replaces the hormone directly, GHRPs work by amplifying the body's own GH production. This distinction matters: GHRP-mediated GH release preserves the normal pulsatile pattern of GH secretion, and the magnitude of GH release is modulated by somatostatin tone, providing a built-in safety mechanism against excessive GH levels.[2]
GHRP-2 in Children with Short Stature
The most direct pediatric evidence for GHRPs comes from Pihoker et al. (1997), who studied intranasal GHRP-2 in children with short stature over an 8-month treatment period.[3]
Growth velocity was higher during GHRP-2 treatment than during pretreatment and post-treatment evaluation periods. No significant side effects or toxicities were observed. However, serum IGF-1 and IGFBP-3 levels did not increase significantly during treatment, suggesting the GH elevations may not have been sustained enough to produce robust downstream signaling. The authors concluded that formulations or routes of administration allowing longer duration of action would be needed to make GHRP-2 a practical therapy.
This finding aligns with a broader challenge for GHRPs: their short half-life (typically minutes) means the GH pulses they induce are brief. The differences between GHRP-2 and GHRP-6 include appetite effects, potency, and selectivity, but both share this pharmacokinetic limitation in pediatric use.
GHRP Diagnostic Applications
Before GHRPs were tested as therapies, Bercu et al. (1997) established their utility as diagnostic tools. Sequential administration of GHRH and GHRP-2 provided a reliable assessment of pituitary GH secretory capacity, differentiating children with true GH deficiency from those with functional growth delay.[4]
Children with organic GH deficiency (pituitary damage or congenital malformation) showed blunted responses to both GHRH and GHRP-2. Children with idiopathic short stature but intact pituitary function showed preserved GH responses, particularly to the combination stimulus. This diagnostic use remains clinically relevant, as it helps distinguish which children will benefit from GH replacement versus those whose short stature has other causes.
Oral GH Secretagogues: Ibutamoren (MK-677)
Ibutamoren mesylate (MK-677) is a nonpeptide, orally active growth hormone secretagogue that acts through the same GHS-R1a receptor as GHRPs. Its oral bioavailability and longer half-life (approximately 6 hours) addressed the main limitation of injectable GHRPs.
Codner et al. (2001) conducted a controlled trial of oral ibutamoren in children with GH deficiency. Treatment increased mean 24-hour GH concentration, peak GH levels, and serum IGF-1 levels in GH-deficient children compared to baseline.[5]
The study established that oral GH secretagogues could meaningfully stimulate the GH-IGF-1 axis in GH-deficient children, but the magnitude of the effect was modest compared to direct rhGH replacement. The GH responses were dose-dependent, and the treatment was well tolerated. However, ibutamoren was never developed to FDA approval for pediatric GHD, and its clinical use in children remains limited to research settings. More detail on its pharmacology is available in the article on MK-677 as a growth hormone secretagogue.
GHRH Analogs: From Sermorelin to CJC-1295
Growth hormone-releasing hormone analogs represent a different strategy. Rather than acting on the ghrelin/GHS-R1a pathway, they directly stimulate the GHRH receptor on pituitary somatotrophs, mimicking the hypothalamic signal that normally triggers GH release.
Sermorelin
Sermorelin (GRF 1-29) was the first GHRH analog approved for pediatric GHD in the United States. It is a 29-amino-acid peptide corresponding to the first 29 residues of native GHRH, retaining full biological activity. Subcutaneous sermorelin produced increases in growth velocity in GH-deficient children, and it was FDA-approved in 1997. It preserved the normal pulsatile GH pattern and carried a lower theoretical risk of the long-term complications associated with supraphysiologic GH replacement.
However, sermorelin had practical limitations. It required daily injections (like rhGH), its efficacy was less predictable than direct GH replacement (because it depends on residual pituitary function), and the manufacturer eventually discontinued it for commercial reasons. The broader profile of sermorelin as a growth hormone-releasing peptide contextualizes its role beyond pediatric use.
Marshall et al. (1996) demonstrated that episodic (pulsatile) GHRH administration was more effective than continuous infusion in promoting growth in GH-deficient children, a finding consistent with the known physiology that GH release requires rhythmic GHRH stimulation rather than sustained exposure.[6]
CJC-1295: Long-Acting GHRH
CJC-1295 addressed sermorelin's short half-life through a drug affinity complex (DAC) that extends its circulation time dramatically. Teichman et al. (2006) showed that a single injection of CJC-1295 in healthy adults produced prolonged stimulation of GH and IGF-1 secretion, with elevated GH levels lasting up to 6 days and elevated IGF-1 persisting for 9-11 days after a single dose.[7]
Critically, Alba et al. (2006) confirmed that CJC-1295 preserved the normal pulsatile pattern of GH secretion, unlike direct GH injection which produces a pharmacologic spike. The pituitary continued to release GH in physiologic bursts even under continuous CJC-1295 stimulation, with peak GH and mean GH concentrations increasing 2 to 10-fold.[8]
CJC-1295 has not been studied in pediatric GHD specifically, and it remains an investigational compound. The detailed pharmacology is covered in CJC-1295: the GHRH analog explained and CJC-1295's effects on IGF-1 elevation.
Long-Acting Growth Hormone Formulations
The most active area of development in pediatric GHD treatment is long-acting GH formulations that reduce injection frequency from daily to weekly. Several have completed phase III trials or received regulatory approval:
Somatrogon received FDA approval in 2023 for pediatric GHD. In a phase III trial of treatment-naive prepubertal children, once-weekly somatrogon (0.66 mg/kg/week) produced an annualized height velocity of 10.10 cm/year versus 9.78 cm/year for daily somatropin, meeting the non-inferiority endpoint.
Lonapegsomatropin (Skytrofa) was the first FDA-approved weekly GH therapy for pediatric GHD (2021). Phase III data showed weekly lonapegsomatropin produced significantly greater annualized height velocity than daily somatropin over 52 weeks.
Somapacitan has shown non-inferior efficacy to daily GH in phase III pediatric trials and is approved for adult GHD.
These weekly formulations directly address the adherence problem. Reducing 365 injections per year to 52 represents a meaningful quality-of-life improvement for children and families, potentially translating into better real-world growth outcomes.
Comparing Peptide Approaches
| Approach | Mechanism | Route | Frequency | Pediatric Evidence |
|---|---|---|---|---|
| rhGH (somatropin) | Direct GH replacement | SC injection | Daily | Decades of data, FDA-approved |
| Long-acting GH | Direct GH replacement | SC injection | Weekly | Phase III trials, FDA-approved |
| GHRP-2 | Ghrelin receptor agonist | Intranasal/SC | Multiple daily | Limited, short half-life issue |
| Ibutamoren (MK-677) | Oral GHS-R1a agonist | Oral | Daily | Controlled trial in GHD children |
| Sermorelin | GHRH receptor agonist | SC injection | Daily | FDA-approved (discontinued) |
| CJC-1295 | Long-acting GHRH analog | SC injection | Weekly | Adults only, not studied in children |
| Mecasermin | Direct IGF-1 replacement | SC injection | Twice daily | FDA-approved for severe IGF-1 deficiency |
Each approach has a specific niche. Direct GH replacement (rhGH or long-acting variants) remains the standard for children with confirmed GH deficiency because it is the most reliable way to normalize IGF-1 levels and growth velocity. GH secretagogues and GHRH analogs require intact pituitary function, making them unsuitable for children with organic GHD from pituitary damage. Mecasermin fills the narrow gap for children with GH receptor defects or GH gene deletions who cannot respond to either GH or GH-releasing agents.
The Bottom Line
Recombinant human growth hormone remains the standard treatment for pediatric GH deficiency, producing first-year catch-up growth of 8-10 cm/year and enabling over 90% of treated children to reach normal adult height. Peptide alternatives including GHRP-2, ibutamoren, and GHRH analogs have demonstrated the ability to stimulate endogenous GH release in children, but none has matched the reliability of direct GH replacement. The most clinically significant recent development is the approval of long-acting weekly GH formulations (somatrogon, lonapegsomatropin), which maintain equivalent efficacy while reducing injection burden from daily to weekly. GH secretagogues and GHRH analogs require intact pituitary function, limiting their use to specific subpopulations.